Current treatment status-Did not start treatment yet Posts on Medivizor
Navigation Menu

Current treatment status-Did not start treatment yet Posts on Medivizor

Dasatinib and blinatumomab for patients with Philadelphia chromosome positive acute lymphoblastic leukemia

Dasatinib and blinatumomab for patients with Philadelphia chromosome positive acute lymphoblastic leukemia

Posted by on Jan 4, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the combination of dasatinib (Sprycel) and blinatumomab (Blincyto) as a first-line therapy in patients with Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL).  This study concluded that this treatment combination led to better response and survival in these...

Read More

Evaluating long-term active surveillance for early-stage prostate cancer.

Evaluating long-term active surveillance for early-stage prostate cancer.

Posted by on Dec 28, 2020 in Prostate cancer | 0 comments

In a nutshell This study was carried out to assess the long-term outcomes of men diagnosed with prostate cancer (PC) undergoing active surveillance (AS) and factors that predicted the risk of their cancer spreading (metastasizing). The authors found that AS is a safe and viable option for men with low-risk and carefully-selected intermediate-risk...

Read More

The outcomes of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer

The outcomes of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer

Posted by on Dec 18, 2020 in Lung cancer | 0 comments

In a nutshell The study compared outcomes of lorlatinib (Lorbrena) with crizotinib (Xalkori) in patients with previously untreated advanced non-small-cell lung cancer (NSCLC) with ALK mutations (genetic abnormalities). The main finding was that patients receiving lorlatinib had longer progression-free survival (PFS) and a higher response in the...

Read More

Evaluating long-term outcomes of MRI-guided ultrasound ablation for prostate cancer.

Evaluating long-term outcomes of MRI-guided ultrasound ablation for prostate cancer.

Posted by on Dec 13, 2020 in Prostate cancer | 0 comments

In a nutshell This study was carried out to assess the long-term safety and effectiveness of magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) in patients with localized prostate cancer. The authors found that TULSA was safe and effective, with preserved quality of life. Some background Prostate cancer is one...

Read More

Comparing chemotherapy-free treatments for patients with treatment naïve chronic lymphocytic leukemia

Comparing chemotherapy-free treatments for patients with treatment naïve chronic lymphocytic leukemia

Posted by on Oct 17, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate three different chemotherapy-free treatment regimens for patients with chronic lymphocytic leukemia.  This study concluded that acalabrutinib (Calquence) plus obinutuzumab (Gazyva) improved survival without cancer worsening for these patients.   Some background Chemotherapy-free...

Read More

Evaluating the impact of surgical removal of tumors in non-Hodgkin lymphoma.

Evaluating the impact of surgical removal of tumors in non-Hodgkin lymphoma.

Posted by on Sep 29, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the effectiveness of complete surgical removal of aggressive non-Hodgkin lymphoma (NHL). The authors found that in young patients with diffuse large B-cell lymphoma (DLBCL) may benefit from complete surgical removal of the tumor before immunochemotherapy (ICT).  Some background Lymphoma is a cancer that...

Read More

Should azacitidine and venetoclax be used to treat older patients with acute myeloid leukemia?

Should azacitidine and venetoclax be used to treat older patients with acute myeloid leukemia?

Posted by on Sep 27, 2020 in Leukemia | 0 comments

In a nutshell This trial was carried out to assess the effectiveness of azacitidine (Vidaza) in combination with venetoclax (Venclexta) for the treatment of untreated acute myeloid leukemia (AML) in older adults. The authors concluded that this combination prolonged survival and induced more remissions in these patients. Some...

Read More

Are radiotherapy and surgery equally good at treating localized prostate cancer?

Are radiotherapy and surgery equally good at treating localized prostate cancer?

Posted by on Sep 26, 2020 in Prostate cancer | 0 comments

In a nutshell This study compared surgery and radiotherapy for treating localized prostate cancer. They found no significant difference in survival between the two treatments. Some background Localized prostate cancer (cancer which has not spread beyond the prostate gland) can be treated with either surgery, radiotherapy, or monitoring without...

Read More

An examination of pertuzumab and trastuzumab as breast cancer treatment before surgery in a real-life setting

An examination of pertuzumab and trastuzumab as breast cancer treatment before surgery in a real-life setting

Posted by on Sep 26, 2020 in Breast cancer | 0 comments

In a nutshell This study examined the effectiveness and safety of the drug combination pertuzumab (Perjeta) and trastuzumab (Herceptin) as a treatment for breast cancer (BC) with positive HER2 (human epidermal growth factor receptor 2) before surgery to remove the tumor in a real-world setting. The data showed that this...

Read More

Evaluating sorafenib maintenance therapy in patients with acute myeloid leukemia with FLT3-ITD mutation undergoing allogeneic HSCT

Evaluating sorafenib maintenance therapy in patients with acute myeloid leukemia with FLT3-ITD mutation undergoing allogeneic HSCT

Posted by on Sep 25, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated outcomes of sorafenib (Nexavar) maintenance therapy after allogeneic hematopoietic stem cell transplantation (alloHSCT) in patients with acute myeloid leukemia (AML) carrying FLT3-ITD mutation (abnormal gene). The authors found that this therapy was effective and tolerable after aHSCT in such patients. Some...

Read More